Protagonist Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders on June 20, 2024
Ticker: PTGX · Form: DEF 14A · Filed: Apr 26, 2024 · CIK: 1377121
Sentiment: neutral
Topics: Annual Meeting, Proxy Statement, Director Election, Executive Compensation, Authorized Shares
TL;DR
<b>Protagonist Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, to elect directors, approve executive compensation, ratify auditors, and vote on a stock increase.</b>
AI Summary
Protagonist Therapeutics, Inc (PTGX) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Protagonist Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, at 10:00 a.m. Pacific Time. The meeting agenda includes the election of three Class II director nominees, advisory approval of executive compensation, and ratification of Ernst & Young LLP as the independent auditor for fiscal year 2024. Stockholders will vote on a proposed amendment to increase the authorized shares of common stock from 90,000,000 to 180,000,000. The meeting will be conducted exclusively online via live audio webcast at www.virtualshareholdermeeting.com/PTGX2024. Online check-in for the virtual meeting will commence at 9:45 a.m. Pacific Time.
Why It Matters
For investors and stakeholders tracking Protagonist Therapeutics, Inc, this filing contains several important signals. The company is seeking stockholder approval to significantly increase its authorized common stock, which could impact future fundraising and equity-based compensation strategies. The virtual format for the annual meeting may affect stockholder engagement and participation compared to in-person events.
Risk Assessment
Risk Level: low — Protagonist Therapeutics, Inc shows low risk based on this filing. This filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would alter the company's risk profile.
Analyst Insight
Stockholders should review the proposals regarding director elections, executive compensation, auditor ratification, and the significant increase in authorized shares before the June 20, 2024 meeting.
Key Numbers
- June 20, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders)
- 10:00 a.m. Pacific Time — Meeting Start Time (Scheduled start time for the virtual Annual Meeting)
- 9:45 a.m. Pacific Time — Check-in Start Time (Time when online check-in begins for the virtual meeting)
- 3 — Director Nominees (Number of Class II director nominees to be elected)
- 2027 — Director Term End (Year until which elected directors will hold office)
- 180,000,000 — Proposed Authorized Shares (New target for authorized common stock shares)
- 90,000,000 — Current Authorized Shares (Existing number of authorized common stock shares)
Key Players & Entities
- Protagonist Therapeutics, Inc. (company) — Registrant and filer of the proxy statement
- June 20, 2024 (date) — Date of the Annual Meeting of Stockholders
- Ernst & Young LLP (company) — Proposed independent registered public accounting firm
- 180,000,000 (dollar_amount) — Proposed increase in authorized shares of common stock
- 90,000,000 (dollar_amount) — Current authorized shares of common stock
- 10:00 a.m. Pacific Time (time) — Start time of the Annual Meeting
- 9:45 a.m. Pacific Time (time) — Start time for online check-in
FAQ
When did Protagonist Therapeutics, Inc file this DEF 14A?
Protagonist Therapeutics, Inc filed this Proxy Statement (DEF 14A) with the SEC on April 26, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Protagonist Therapeutics, Inc (PTGX).
Where can I read the original DEF 14A filing from Protagonist Therapeutics, Inc?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Protagonist Therapeutics, Inc.
What are the key takeaways from Protagonist Therapeutics, Inc's DEF 14A?
Protagonist Therapeutics, Inc filed this DEF 14A on April 26, 2024. Key takeaways: Protagonist Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, at 10:00 a.m. Pacific Time.. The meeting agenda includes the election of three Class II director nominees, advisory approval of executive compensation, and ratification of Ernst & Young LLP as the independent auditor for fiscal year 2024.. Stockholders will vote on a proposed amendment to increase the authorized shares of common stock from 90,000,000 to 180,000,000..
Is Protagonist Therapeutics, Inc a risky investment based on this filing?
Based on this DEF 14A, Protagonist Therapeutics, Inc presents a relatively low-risk profile. This filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would alter the company's risk profile.
What should investors do after reading Protagonist Therapeutics, Inc's DEF 14A?
Stockholders should review the proposals regarding director elections, executive compensation, auditor ratification, and the significant increase in authorized shares before the June 20, 2024 meeting. The overall sentiment from this filing is neutral.
Risk Factors
- Stockholder Approval for Share Increase [low — regulatory]: The company requires stockholder approval to amend its Certificate of Incorporation to increase the number of authorized shares of common stock, a standard procedural requirement.
Key Dates
- 2024-06-20: Annual Meeting of Stockholders — Key date for voting on director nominees, executive compensation, auditor ratification, and stock authorization.
Filing Stats: 4,889 words · 20 min read · ~16 pages · Grade level 10.8 · Accepted 2024-04-26 16:31:10
Filing Documents
- tm242713-d7_def14a.htm (DEF 14A) — 674KB
- lg_protagonist-pn.jpg (GRAPHIC) — 20KB
- bc_companytsr-4c.jpg (GRAPHIC) — 76KB
- bc_netloss-4c.jpg (GRAPHIC) — 70KB
- px_24protagonistpage01-bw.jpg (GRAPHIC) — 263KB
- px_24protagonistpage02-bw.jpg (GRAPHIC) — 234KB
- 0001104659-24-052999.txt ( ) — 2876KB
- ptgx-20240331.xsd (EX-101.SCH) — 7KB
- ptgx-20240331_def.xml (EX-101.DEF) — 5KB
- ptgx-20240331_lab.xml (EX-101.LAB) — 24KB
- ptgx-20240331_pre.xml (EX-101.PRE) — 5KB
- tm242713-d7_def14a_htm.xml (XML) — 97KB
From the Filing
tm242713-6_nonfiling - block - 6.468765s UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 PROTAGONIST THERAPEUTICS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than The Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. 7707 Gateway Blvd., Suite 140 Newark, California 94560 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held On June 20, 2024 Dear Stockholder: You are cordially invited to attend the 2024 Annual Meeting of Stockholders (the "Annual Meeting") of Protagonist Therapeutics, Inc., a Delaware corporation (the "Company"). The meeting will be held exclusively online via live audio webcast at www.virtualshareholdermeeting.com/PTGX2024 on Thursday, June 20, 2024 at 10:00 a.m. Pacific Time for the following purposes: 1. To elect the three Class II director nominees named in the Proxy Statement to hold office until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified. 2. To approve, on an advisory basis, the compensation of the Company's named executive officers. 3. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2024. 4. To approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of our common stock from 90,000,000 to 180,000,000. 5. To conduct any other business that may be properly brought before the meeting or any adjournment or postponement thereof. These items of business are more fully described in the Proxy Statement accompanying this Notice. The Annual Meeting will be held virtually this year. Online check-in will begin at 9:45 a.m. Pacific Time and you should allow ample time for the check-in procedures. You will not be able to attend the Annual Meeting in person. The record date for the Annual Meeting is April 24, 2024. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment or postponement thereof. To participate in the meeting, you must have your 16-digit control number shown on your Notice of Internet Availability of Proxy Materials or on the instructions that accompanied your proxy materials. Instructions for accessing the virtual Annual Meeting are provided in the Proxy Statement. In the event of a technical malfunction or other situation that the meeting chair determines may affect the ability of the Annual Meeting to satisfy the requirements for a meeting of stockholders to be held by means of remote communication under the Delaware General Corporation Law, or that otherwise makes it advisable to adjourn the Annual Meeting, the meeting chair or secretary will convene the meeting at 11:00 a.m. Pacific Time on the date specified above and at the Company's address specified above solely for the purpose of adjourning the meeting to reconvene at a date, time and physical or virtual location announced by the meeting chair or secretary. Under either of the foregoing circumstances, we will post information regarding the announcement on the Investors page of the Company's website at www.protagonist-inc.com . By Order of the Board of Directors, /s/ Dinesh V. Patel, Ph.D. Dinesh V. Patel, Ph.D. President and Chief Executive Officer Newark, California April 26, 2024 Whether or not you expect to participate in the virtual Annual Meeting, please vote as promptly as possible in order to ensure your representation at the Annual Meeting. You may vote online or, if you requested printed copies of the proxy materials, by telephone or by using the proxy card or voting instruction form provided with the printed proxy materials. 7707 Gateway Blvd., Suite 140 Newark, California 94560 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS Thursday, June 20, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice of internet availability of proxy materials? Pursuant to rules adopted by the Securities and Exchange Commission (the "SEC"), we have elected to provide access to our proxy materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the "Notice") because the Board of Directors (the "Board") of Protag